FDA nominee Overton sidesteps mifepristone questions — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Heidi Overton, nominee for FDA commissioner, appeared before the Senate health committee Thursday and repeatedly sidestepped questions about mifepristone, vaccine and food safety misinformation, and Sen. Maggie Hassan's (D-N.H.) ask to name one thing the president had ever been wrong about — which went unanswered.
- Mifepristone, used by an estimated 7.5 million Americans and standard care paired with misoprostol, remains gated by FDA rules requiring special clinician certification, unique pharmacy registration, and patient agreement forms — restrictions the opinion piece contrasts with acetaminophen's estimated 458 annual deaths and over-the-counter birth control pills since 2023.
- Americans United for Life's head told the opinion author he had spoken with Overton five or six times and predicted she would "expose" mifepristone, framing the nomination as an opening for anti-abortion groups to revisit the drug's regulatory status.
- Louisiana has twice turned to the 5th Circuit seeking to end remote mifepristone prescribing — briefly winning a nationwide in-person dispensing order this spring before the Supreme Court paused it — while the FDA's own mifepristone safety review is now scheduled to finish after the midterms.
- About 30% of U.S. abortion patients now receive care via telehealth, often from clinicians in telemedicine shield-law states, an access channel Sen. Josh Hawley (R-Mo.) said during the hearing he wants to halt.
- The FDA has fired more than 3,000 staff in the past year and saw its last commissioner resign after clashing with the White House, leaving Overton to lead an agency the opinion piece argues is already hollowed out and primed for political pressure over scientific judgment.
Why it matters: If confirmed, Overton would oversee an FDA mifepristone safety review deliberately timed to finish after the midterms — meaning the drug's regulatory fate for its 7.5 million users could be settled after voters lose their only political lever, at an agency already stripped of more than 3,000 staff.
Ask SkimNews
